NewsRx

Search our medical news database

Cancer Therapies

Results of Radiation Enhancement By RSR13 Reported

Published in Cancer Weekly, February 16th, 1998

Allos Therapeutics, Inc., Denver, Colorado, announced preliminary outcome results of a Phase Ib study of its radioenhancement agent RSR13 in cancer patients treated concurrently with radiation therapy (RT).

The results were presented at the 10th International Conference on Chemical Modifiers of Cancer Treatment, held in Clearwater, Florida, during January 1998.

RSR13 is a synthetic allosteric modifier of hemoglobin, a new class of pharmaceutical agents. RSR13 is a small molecule that reduces hemoglobin-oxygen binding affinity and increases oxygen delivery from blood to oxygen-deprived tissues. Allos is focusing on the clinical development of RSR13...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook